Empowering people, informing care decisions
Changing the way patients are diagnosed and managed
We provide more than just a test result - our gene expression profile (GEP) tests provide accurate, objective, and personalized information that can help guide informed decisions and improve care for patients with melanocytic lesions, melanoma, or squamous cell carcinoma.
DecisionDx-Melanoma
DecisionDx-Melanoma is a gene expression profile test that provides comprehensive, personalized results to guide risk-aligned management decisions for patients with stage I-III cutaneous melanoma. By harnessing the genetic information within a patient’s tumor biology and incorporating traditional clinicopathologic features, DecisionDx-Melanoma helps to stratify patient risk and provide personalized results regarding a patient's risk of recurrence and/or metastasis and likelihood of sentinel lymph node positivity. DecisionDx-Melanoma can help to improve prognostic accuracy, better inform management decisions and positively impact outcomes – it is the only melanoma prognostic test associated with improved survival.
DecisionDx-SCC
DecisionDx-SCC is a validated 40-GEP test that is designed to identify the risk of nodal or distant metastasis in squamous cell carcinoma (SCC) patients with one or more risk factors, based on the biological profile of 40 genes within their tumor tissue. It is the strongest independent predictor of SCC metastasis.ecision. Dx-SCC results deliver precision patient classification, complementing commonly used traditional risk factors and improving risk assessment in SCC to inform key clinical management decisions, such as if your patient is likely to benefit from adjuvant radiation therapy (ART).
MyPath Melanoma
MyPath Melanoma gene expression profile (GEP) test is designed to provide objective information to aid in the diagnosis and inform management decisions for patients with ambiguous melanocytic lesions. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and malignant lesions based on the expression of 23 genes. By classifying the lesion as benign, intermediate, or malignant, MyPath Melanoma enables physicians to make more definitive diagnoses and more informed management decisions.